CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $133.2 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.23 per share.

The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.51 per share.

The cancer drug developer posted revenue of $66 million in the period, also surpassing Street forecasts. Ten analysts surveyed by Zacks expected $43.5 million.

Blueprint Medicines expects full-year revenue in the range of $180 million to $200 million.

Blueprint Medicines shares have dropped 52% since the beginning of the year. The stock has declined 54% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News